The US company also sells a small-molecule HER2 inhibitor – Tukysa (tucatinib) – which is now partnered with Merck & Co outside the US, Canada and Europe as part of a $4.2 billion alliance ...
Hosted on MSN23d
What to Know About CDK4/6 Inhibitors as Breast Cancer Treatment: Weighing the Risks vs. BenefitsThese are targeted drugs that can be used for women with a common type of breast cancer: hormone receptor-positive and HER2-negative. Currently, there are three CDK4/6 inhibitors approved to treat ...
Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...
Targeted therapies for HER2-negative advanced breast cancer include: PARP inhibitors like olaparib (Lynparza) and talazoparib (Talzenna). These drugs stop a protein known as poly-ADP ribose ...
[166] The HER2 mAb pertuzumab represents a new class of drugs called dimerization inhibitors; these have the potential to block signaling by other HER family receptors, as well as inhibiting ...
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...
Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...
often combined with CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib. HER2-positive breast cancer is effectively treated with HER2-targeted therapies, including trastuzumab ...
In combination with an aromatase inhibitor as the initial endocrine-based therapy for adults with HR+/HER2- advanced or metastatic breast cancer. In combination with fulvestrant for adults with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback